News Image

For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals.

By Mill Chart

Last update: Nov 8, 2023

Uncover the potential of PACIRA BIOSCIENCES INC (NASDAQ:PCRX) as our stock screener's choice for an undervalued stock. NASDAQ:PCRX maintains a strong financial position and offers an appealing valuation. We'll delve into the specifics below.

Valuation Analysis for NASDAQ:PCRX

To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:PCRX has achieved a 9 out of 10:

  • With a Price/Earnings ratio of 10.70, the valuation of PCRX can be described as very reasonable.
  • 87.38% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of PCRX to the average of the S&P500 Index (23.44), we can say PCRX is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 7.67, the valuation of PCRX can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, PCRX is valued cheaper than 91.26% of the companies in the same industry.
  • PCRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 18.82, which is the current average of the S&P500 Index.
  • Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaply inside the industry as 85.44% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 91.26% of the companies listed in the same industry.
  • PCRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • PCRX has a very decent profitability rating, which may justify a higher PE ratio.
  • PCRX's earnings are expected to grow with 25.60% in the coming years. This may justify a more expensive valuation.

Assessing Profitability for NASDAQ:PCRX

ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:PCRX scores a 7 out of 10:

  • With an excellent Return On Assets value of 0.46%, PCRX belongs to the best of the industry, outperforming 82.04% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 0.84%, PCRX belongs to the top of the industry, outperforming 83.01% of the companies in the same industry.
  • PCRX's Return On Invested Capital of 3.49% is amongst the best of the industry. PCRX outperforms 81.55% of its industry peers.
  • With an excellent Profit Margin value of 1.05%, PCRX belongs to the best of the industry, outperforming 82.52% of the companies in the same industry.
  • With an excellent Operating Margin value of 10.15%, PCRX belongs to the best of the industry, outperforming 82.52% of the companies in the same industry.
  • PCRX's Operating Margin has improved in the last couple of years.
  • PCRX has a Gross Margin of 70.12%. This is in the better half of the industry: PCRX outperforms 77.67% of its industry peers.

Assessing Health Metrics for NASDAQ:PCRX

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:PCRX has achieved a 6 out of 10:

  • With a decent Altman-Z score value of 1.95, PCRX is doing good in the industry, outperforming 67.96% of the companies in the same industry.
  • With an excellent Debt to FCF ratio value of 4.03, PCRX belongs to the best of the industry, outperforming 88.83% of the companies in the same industry.
  • PCRX has a Current Ratio of 4.78. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
  • PCRX has a Current ratio of 4.78. This is in the better half of the industry: PCRX outperforms 60.68% of its industry peers.
  • PCRX has a Quick Ratio of 3.74. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.

Understanding NASDAQ:PCRX's Growth Score

ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NASDAQ:PCRX scores a 5 out of 10:

  • Measured over the past years, PCRX shows a very strong growth in Earnings Per Share. The EPS has been growing by 68.62% on average per year.
  • Measured over the past years, PCRX shows a quite strong growth in Revenue. The Revenue has been growing by 18.40% on average per year.
  • PCRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.89% yearly.

More Decent Value stocks can be found in our Decent Value screener.

Check the latest full fundamental report of PCRX for a complete fundamental analysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (2/21/2024, 2:10:50 PM)

29.61

-0.25 (-0.84%)

PCRX News

News Image6 days ago - Pacira BioSciencesPacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
News Image6 days ago - Pacira BioSciencesPacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

– Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator – – Significantly greater...

News Image12 days ago - ChartmillNASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals.

News Image13 days ago - Market News VideoRSI Alert: Pacira BioSciences (PCRX) Now Oversold
News Image14 days ago - Pacira BioSciencesPacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
News Image20 days ago - G.O.A.T. PaddleG.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams

/PRNewswire/ -- Paradise PB Events and G.O.A.T. Paddle, the high performance pickleball company created by and for top players and those who want to compete...

News Image2 months ago - Pacira BioSciencesPacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
News Image2 months ago - Pacira BioSciencesPacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues

TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain...

News Image2 months ago - Market News VideoNotable Wednesday Option Activity: PLCE, PCRX, SYY
News Image2 months ago - Pacira BioSciencesPacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
News Image2 months ago - Pacira BioSciencesPacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

TAMPA, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 42nd Annual J.P....

News Image2 months ago - Seeking AlphaPacira appoints Frank Lee as chief executive officer (NASDAQ:PCRX)

Pacira BioSciences appoints Frank Lee as CEO and board member, succeeding David Stack who will retire but remain in an advisory role for a smooth...

PCRX Links
Follow us for more